CAJ | 학술논문

近来,肠道菌群在代谢性疾病中的作用逐渐受到重视.肠道菌群可影响机体能量摄取,代谢综合征患者肠道菌群种类与正常个体存在差异,由此引发的内毒素血症和胰岛素靶器官的慢性炎性反应影响机体代谢.一些调理肠道菌群的治疗措施,如抗生素、益生菌和益生元等可以调节胃肠激素的分泌,抑制食欲,减弱慢性炎性反应,增加靶器官的胰岛素敏感性.干预肠道菌群有望成为未来代谢性疾病的辅助治疗方法之一.
근래,장도균군재대사성질병중적작용축점수도중시.장도균군가영향궤체능량섭취,대사종합정환자장도균군충류여정상개체존재차이,유차인발적내독소혈증화이도소파기관적만성염성반응영향궤체대사.일사조리장도균군적치료조시,여항생소、익생균화익생원등가이조절위장격소적분비,억제식욕,감약만성염성반응,증가파기관적이도소민감성.간예장도균군유망성위미래대사성질병적보조치료방법지일.
Recently,the gut microbiota is increasingly thought to play an important role in the development of metabolic disorders.Gut microbiota may manipulate energy harvest,the gut microbiota in patients with metabolic diseases is different from that in healthy individuals.The abnormal gut microbiota induced endotoxemia and chronic inflammation of target organs initiate the metabolic disorders.Several strategies (antibiotics,probiotics and prebiotics)focusing on modulation of the gut microbiota can be used to modulate the secretion of gastrointestinal hormones and therefore regulate appetite,improve the chronic inflammation,and promote insulin sensitivity in insulin target organs.Modulation of gut microbiota may become an adjuvant therapy for metabolic disease in future.